EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer

Benjamin C Milgram iD, Deanna R Borrelli, Natasja Brooijmans, Jack A Henderson, Brendan J Hilbert, Michael R Huff, Takahiro Ito, Erica L Jackson, Philip Jonsson, Brendon Ladd, Erin L O'Hearn, Raymond A Pagliarini und 5 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Benjamin C Milgram und 16 weiteren Autor:innen. Beteiligte Einrichtung: Scorpion Therapeutics, 1 Winthrop Square, Boston, Massachusetts 02110, United States. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Erb-b2 Receptor Tyrosine Kinases, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

After L858R and ex19del epidermal growth factor receptor (EGFR) mutations, ex20ins mutations are the third most common class of driver-mutations in non-small cell lung cancer (NSCLC). Unfortunately, first-, second-, and third-generation EGFR tyrosine kinase inhibitors (TKIs) are generally ineffective for ex20ins patients due to insufficient mutant activity and selectivity over wild-type EGFR, leading to dose-limiting toxicities. While significant advances in recent years have been made toward identifying potent EGFR ex20ins mutant inhibitors, mutant vs wild-type EGFR selectivity remains a significant challenge. STX-721 (53) is a potent, irreversible inhibitor of the majority of EGFR/HER2 ex20ins mutants and demonstrates excellent mutant vs wild-type selectivity both in vitro and in vivo. STX-721 is currently in phase 1/2 clinical trials for EGFR/HER2 ex20ins-driven NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErbB ReceptorsErb-b2 Receptor Tyrosine KinasesLung NeoplasmsHumansAnimalsAntineoplastic AgentsExonsMiceMutationProtein Kinase InhibitorsStructure-Activity RelationshipCell Line, TumorRatsDrug Discovery

Substanzen

ErbB ReceptorsErb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsProtein Kinase InhibitorsERBB2 protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Scorpion Therapeutics, 1 Winthrop Square, Boston, Massachusetts 02110, United States.
  • Scorpion Therapeutics, South San Francisco, California 94080, United States.

ORCID-Profile: Benjamin C Milgram

Zitieren

APA

Milgram, B. C., Borrelli, D. R., Brooijmans, N., Henderson, J. A., Hilbert, B. J., Huff, M. R., Ito, T., Jackson, E. L., Jonsson, P., Ladd, B., O'Hearn, E. L., Pagliarini, R. A., Roberts, S. A., Ronseaux, S., Stuart, D. D., Wang, W., & Guzman-Perez, A. (2025). Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02377

Vancouver

Milgram BC, Borrelli DR, Brooijmans N, Henderson JA, Hilbert BJ, Huff MR, et al. Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02377

BibTeX
@article{Milgram2025,
  author = {Milgram, Benjamin C and Borrelli, Deanna R and Brooijmans, Natasja and Henderson, Jack A and Hilbert, Brendan J and Huff, Michael R and Ito, Takahiro and Jackson, Erica L and Jonsson, Philip and Ladd, Brendon and O'Hearn, Erin L and Pagliarini, Raymond A and Roberts, Simon A and Ronseaux, Sébastien and Stuart, Darrin D and Wang, Weixue and Guzman-Perez, Angel},
  title = {Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02377}
}
Kostenlos starten →